News

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences is providing millions of Czech crowns in support of a new endowed chair at the Faculty of Sciences, Charles University.

Prague, 6 June 2019 – Two distinguished Czech academic institutes in the field of natural scienc-es, the Faculty of Science, Charles University (FOS) and the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), have reached an agreement on the creation of a joint endowed chair for the development and testing of new drugs. Millions of Czech crowns in fund-ing for the new position is being provided by IOCB, which will help attract a leading foreign sci-entist to the Czech Republic and allow them to form their own research group focusing on the discovery and development of new antiparasitics.

As part of its strategy to deepen collaboration with Czech universities, IOCB has introduced a new en-dowed chair concept and established a program called Charles University, Faculty of Science-IOCB Prague Chair, which makes it possible to overcome the salary constraints of the university and attract renowned experts to the Czech Republic for four-year appointments that are not directly tied to IOCB. Funding for the program is being coordinated by IOCB Tech, a subsidiary of IOCB. The company has already provided more than 3.3 million Czech crowns in financial support.

“Collaboration with universities is of strategic importance to us,” explains IOCB director Dr. Zdeněk Hostomský. “The partnership with the Charles University Faculty of Science is the natural result of a joint effort to share human resources and collaborate together on research projects. One of our goals in supporting this new endowed chair is to increase the international prestige of Czech research insti-tutes and, in the long run, assist in making important discoveries in the development of new drugs to ultimately benefit the whole of society.”

“The partnership between the Faculty of Science at Charles University and IOCB is natural and very deep,” says Prof. Jiří Zima, dean of FOS. “Not only do we share a number of employees on a part-time basis at both institutes, we also have a total of eight co-accredited doctoral study programs. Employees and students alike can make use of the cutting-edge laboratories at both institutes, which in today’s world of research represents a considerable competitive advantage. Moreover, IOCB provides our best students with long-term support in the form of scholarships, which, of course, further deepens this al-ready outstanding partnership. We’re also pleased that our collaboration has advanced to the point of supporting leading foreign professors,” adds Prof. Zima.

The first distinguished individual appointed to the position of Charles University, Faculty of Science-IOCB Prague Chair is Dr. Martin Zoltner, who will be working in Vestec at the Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV). Dr. Zoltner comes to the center from the University of Dundee in Scotland, where he conducted research in new antimalarials and drugs targeting the causative agent of sleeping sickness, the endoparasite Trypanosoma brucei.

“Dr. Zoltner’s task is to establish a new laboratory modelled after the Drug Discovery Unit at the Univer-sity of Dundee to test possibilities for applying the promising results of basic research in the develop-ment of new antiparasitic drugs. Thus, the laboratory will help to bridge certain gaps between basic re-search and the pharmaceutical industry,” says parasitologist Prof. Jan Tachezy in describing Dr. Zolt-ner’s role in the project.

In terms of expertise, IOCB is the leader among Czech academic institutes in the technological transfer of basic research results into practice. One of the jobs of the newly created group for the development and testing of drugs headed by Martin Zoltner will be to evaluate the potential of the findings of 15 re-search groups at the Center for Research of Pathogenicity and Virulence of Parasites.

“We’re happy we can meaningfully draw upon our successes in commercialization to support new re-search in the field of drug discovery,” says IOCB deputy director and IOCB Tech director Prof. Martin Fusek.